WillItSurvive
Medical technology and health companies · United States

Redox

redoxengine.com ↗

Redox connects hospitals and health apps to EHRs like Epic through one integration layer.

Losing its protection
Assessed 22 July 2026 · Evidence as of 22 July 2026
The structural protection is eroding.
On the recordSince 22 July 2026 · Checkable from by mid-2026 · Every call on the record Checkpoint: May 2025 convertible note conversion reveals whether Redox raises up, flat, or down
The call

Redox built real distribution that took years to copy, but a big network alone does not stop regulation and AI from squeezing what it charges for that access.

Redox built a network that links over 12,000 hospitals and clinics together so their computer systems can share patient data. They spent a decade building this, which is hard to copy. But three forces are squeezing them at once: regulators are now requiring hospitals to connect directly to each other without middlemen like Redox, Epic and Oracle are adding their own connection tools to keep hospitals locked in, and artificial intelligence is starting to do the translation work that Redox charges for. Redox launched AI tools in June 2026 to become more like an AI company than a connector service, but only 70 customers tried it in the first three weeks, which is very small. The biggest clue to Redox's real health will come whenever they raise money again or convert a recent loan into stock. If they can get investors excited about that, they probably have a path forward. If not, Redox may slowly shrink even if it stays in business.

Why
01
AI pressure: Generative AI/LLM tools automating HL7/FHIR mapping. AI can now write the data-mapping code Redox sells as a service, so Redox built its own AI Assistant to stay ahead of that. Could AI do the core job? Only partly.
02
Bigger players: Epic Systems and Oracle Health (Cerner). Epic keeps expanding native APIs, letting hospitals skip Redox for simple connections while TEFCA standardizes plumbing Redox used to charge for. Could a giant copy it? Probably.
03
What protects it. 12,000+ connected organizations and 100+ EHR connectors took a decade to build and are costly for any single rival to replicate.
What would change this call
Redox's May 2025 convertible note converts (or is disclosed) at a priced valuation. Reveals whether Redox raised at, above, or below its 2021 $310M valuation.
AI Assistant Suite user count reported at end of 2026. Shows whether the AI pivot scaled past 70 users or stayed stagnant.
CMS/TEFCA QHIN designation list adds or excludes Redox through 2026-2028. Indicates whether Redox gains federal standing or stays a private network competing with standardized rails.
Key numbers
  • No priced round since Feb 2021, ~$310M valuation (2021-02-24)
  • AI Assistant Suite had ~70 users post-GA (2026-06)
  • 20B+ healthcare transactions handled in trailing 12 months (2026-02-28)
Named risks
  • No priced equity round since Feb 2021; unpriced convertible note raised May 2025 signals funding strain. Severity: high
  • Core HL7/FHIR mapping value-add is directly automatable by generative AI and agentic tools. Severity: high
  • TEFCA and CMS interoperability regulation standardizing connectivity Redox currently monetizes. Severity: medium
  • Investor-placed CEO since Nov 2023 suggests prior governance or performance concerns. Severity: medium
  • New AI Assistant Suite adoption modest (~70 users) three weeks post-launch, unproven pivot. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Health Gorillalosing toHealth Gorilla holds federal QHIN designation Redox lacks, per comparison dated 2026-05-19
Rhapsodylosing toRhapsody ranked #1 by KLAS 15 consecutive years for integration engines, report dated 2026-05-11
Epic SystemscontestingEpic's improving native APIs erode demand for third-party integration layers like Redox
1upHealthcontesting1upHealth focuses on FHIR-native CMS/payer compliance APIs, named as alternative, 2026-05-19
Particle HealthcontestingFrequently named alongside Redox in interoperability comparison content, 2026-05-14
Questions people ask
Is Redox profitable in 2026?
Redox has not disclosed profitability. Third-party revenue estimates diverge wildly, from ~$51.5M to ~$181M for 2024. Its last priced funding round was a $45M Series D in February 2021 at ~$310.5M valuation, with no new priced round since, and an unpriced convertible note raised May 2025.
Could AI replace Redox?
Redox's core work, translating HL7/FHIR healthcare data between systems, is exactly the mapping task generative AI is automating. Redox launched an MCP server and AI Assistant Suite on June 23, 2026 to reposition as AI infrastructure, but adoption was only about 70 users three weeks post-launch.
Who is Redox's biggest competitor?
Rhapsody, ranked #1 by KLAS for 15 consecutive years in enterprise integration engines per a May 2026 report, and Health Gorilla, a federally designated QHIN, a status Redox lacks, are cited as Redox's closest rivals in healthcare interoperability.
Who owns Redox?
Redox is privately held and venture-backed, with investors including Adams Street Partners, Battery Ventures, RRE Ventures, .406 Ventures, Avenir, Intermountain Healthcare, and Dreamit Ventures. No IPO has been filed as of 2026.
Has Redox had layoffs?
No confirmed mass layoff has been publicly reported, but third-party headcount trackers showed a roughly 7.4% year-over-year decline to 187 employees as of June 2026, alongside continued hiring for AI and product roles.
What is Redox's AI strategy?
On June 23, 2026 Redox launched an MCP server, an AI Assistant Suite, and intelligent in-flight data processing, positioning itself as an AI data infrastructure layer for healthcare AI apps. Early adoption was about 70 users in the first three weeks post-launch.
Timeline
  • 2026-06-23Launched MCP server and AI Assistant Suite, reported ~70 users three weeks post-GA
  • 2025-10-28Announced core platform expansion adding enrichment and orchestration capabilities
  • 2025-05Raised unpriced convertible note, no new valuation disclosed
  • 2025-04-02Joined CommonWell Health Alliance to support TEFCA participation
  • 2023-11-03Co-founder Luke Bonney steps down as CEO, investor-linked Trip Hofer named CEO
  • 2021-02-24Closed $45M Series D led by Adams Street Partners at ~$310.5M post-money valuation
Revision history
22 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
NeuralinkKingmed DiagnosticsMeinian Onehealth
More in Medical technology and health companies →
Sources